Price Action to Note: A Reversal for AxoGen, Inc. Is Not Near. The Stock Rises Again

Price Action to Note: A Reversal for AxoGen, Inc. Is Not Near. The Stock Rises Again

The stock of AxoGen, Inc. (NASDAQ:AXGN) is a huge mover today! About 1.12M shares traded hands or 818.68% up from the average. AxoGen, Inc. (NASDAQ:AXGN) has risen 61.25% since March 4, 2016 and is uptrending. It has outperformed by 53.21% the S&P500.
The move comes after 6 months positive chart setup for the $248.92 million company. It was reported on Oct, 7 by We have $23.76 PT which if reached, will make NASDAQ:AXGN worth $398.27 million more.

Analysts await AxoGen, Inc. (NASDAQ:AXGN) to report earnings on November, 3. They expect $-0.08 earnings per share, up 27.27% or $0.03 from last year’s $-0.11 per share. After $-0.09 actual earnings per share reported by AxoGen, Inc. for the previous quarter, Wall Street now forecasts -11.11% EPS growth.

According to Zacks Investment Research, “AxoGen Corp. is a regenerative medicine company engaged in the development and commercialization of technologies for peripheral nerve reconstruction and regeneration. It offers products for the repair of peripheral nerve injuries. AxoGen Corp was formerly known as LecTec Corporation.”

More important recent AxoGen, Inc. (NASDAQ:AXGN) news were published by: which released: “News AxoGen Inc.AXGN” on May 17, 2012, also published article titled: “AxoGen, Inc. to Participate at the 28th Annual ROTH Growth Conference”, published: “CFO Moves: Delphi Automotive, Hain Celestial Group, AxoGen Inc.” on March 01, 2016. More interesting news about AxoGen, Inc. (NASDAQ:AXGN) was released by: and their article: “AxoGen, Inc.’s AvanceĀ® Nerve Graft Data to be Presented at 2016 Federation of …” with publication date: June 21, 2016.

AXGN Company Profile

AxoGen, Inc. (AxoGen), incorporated on June 20, 1977, is a medical technology firm focused on peripheral nerve repair. The Firm provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. The Company’s regenerative medicine products include Avance Nerve Graft, a processed nerve allograft for bridging severed nerves without the comorbidities associated with a nerve autograft additional surgical site; AxoGuard Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for repair of severed nerves, and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves. The Firm also sells AxoTouch Two Point Discriminator, a measurement tool for determining innervation density and sensory function.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment